X Bioscience PCL (BKK:XBIO)
Thailand · Delayed Price · Currency is THB 0.0700
-0.0100 (-12.50%)
At close: Feb 10, 2026
X Bioscience PCL Income Statement
Financials in millions THB. Fiscal year is January - December.
Millions THB. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 204.63 | 319.24 | 311.77 | 344.49 | 254.04 | 415.62 | |
Revenue Growth (YoY) | -31.09% | 2.40% | -9.50% | 35.60% | -38.88% | -2.13% |
Cost of Revenue | 123.17 | 180.63 | 159.67 | 172.3 | 126.82 | 285.99 |
Gross Profit | 81.45 | 138.61 | 152.11 | 172.18 | 127.23 | 129.62 |
Selling, General & Admin | 479.05 | 389.82 | 272.53 | 455.41 | 227.79 | 264.32 |
Operating Expenses | 479.05 | 389.82 | 272.53 | 455.41 | 227.79 | 261.26 |
Operating Income | -397.59 | -251.21 | -120.43 | -283.23 | -100.56 | -131.63 |
Interest Expense | -27.13 | -34.29 | -39.94 | -56.52 | -14.45 | -16.58 |
Interest & Investment Income | - | - | - | - | 0.01 | 0.14 |
Currency Exchange Gain (Loss) | - | - | - | - | - | 7.18 |
Other Non Operating Income (Expenses) | 8.81 | 7.58 | 11.72 | 3.33 | 9.45 | 4.13 |
EBT Excluding Unusual Items | -415.91 | -277.92 | -148.65 | -336.41 | -105.55 | -136.76 |
Gain (Loss) on Sale of Assets | 18.53 | - | - | - | - | -119.79 |
Asset Writedown | - | - | - | - | - | 22.14 |
Pretax Income | -397.39 | -277.92 | -148.65 | -336.41 | -105.55 | -234.41 |
Income Tax Expense | -15.84 | -15.84 | -1.13 | -5.65 | -5.65 | 2.72 |
Earnings From Continuing Operations | -381.54 | -262.07 | -147.52 | -330.77 | -99.9 | -237.13 |
Earnings From Discontinued Operations | -16.95 | - | - | -245.22 | -176.55 | - |
Net Income to Company | -398.49 | -262.07 | -147.52 | -575.99 | -276.45 | -237.13 |
Minority Interest in Earnings | 2.34 | 1.85 | - | - | - | -1.68 |
Net Income | -396.15 | -260.22 | -147.52 | -575.99 | -276.45 | -238.81 |
Net Income to Common | -396.15 | -260.22 | -147.52 | -575.99 | -276.45 | -238.81 |
Shares Outstanding (Basic) | 279 | 184 | 125 | 116 | 116 | 97 |
Shares Outstanding (Diluted) | 279 | 184 | 125 | 116 | 116 | 97 |
Shares Change (YoY) | 83.32% | 46.88% | 7.78% | - | 19.79% | -6.86% |
EPS (Basic) | -1.42 | -1.41 | -1.18 | -4.95 | -2.38 | -2.46 |
EPS (Diluted) | -1.42 | -1.41 | -1.18 | -4.95 | -2.38 | -2.46 |
Free Cash Flow | -73.52 | -73.77 | -133.59 | -291.22 | -212.57 | -67.58 |
Free Cash Flow Per Share | -0.26 | -0.40 | -1.07 | -2.50 | -1.83 | -0.70 |
Gross Margin | 39.81% | 43.42% | 48.79% | 49.98% | 50.08% | 31.19% |
Operating Margin | -194.30% | -78.69% | -38.63% | -82.22% | -39.58% | -31.67% |
Profit Margin | -193.59% | -81.51% | -47.32% | -167.20% | -108.82% | -57.46% |
Free Cash Flow Margin | -35.93% | -23.11% | -42.85% | -84.54% | -83.67% | -16.26% |
EBITDA | -371.02 | -224.53 | -102.69 | -189.44 | -13.51 | -65.57 |
EBITDA Margin | -181.31% | -70.33% | -32.94% | -54.99% | -5.32% | -15.78% |
D&A For EBITDA | 26.57 | 26.68 | 17.73 | 93.79 | 87.05 | 66.06 |
EBIT | -397.59 | -251.21 | -120.43 | -283.23 | -100.56 | -131.63 |
EBIT Margin | -194.30% | -78.69% | -38.63% | -82.22% | -39.58% | -31.67% |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.